Strona główna
  • Zamawiaj do paczkomatu
  • Płać wygodnie
  • Obniżka
Generic Drugs: The Pay-for-Delay Problem

Generic Drugs: The Pay-for-Delay Problem

9781611220711
535,44 zł
481,89 zł Zniżka 53,55 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 481,89 zł
Ilość
Od 4 do 6 tygodni

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD, Pocztę, email (dla ebooków). Kliknij po więcej

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni*. Kliknij po więcej szczegółów

Opis
Brand-name pharmaceutical companies can delay generic competition that lowers prices by agreeing to pay a generic competitor to hold its competing product off the market for a certain period of time. These so-called pay-for-delay agreements have arisen as part of patent litigation settlement agreements between brand-name and generic pharmaceutical companies. Pay-for-delay agreements are win-win for the companies:: brand name pharmaceutical prices stay high, and the brand and generic share the benefits of the brands monopoly profits. Consumers lose, however:: they miss out on generic prices that can be as much as 90 percent less than brand prices. For example, brand-name medication that costs $300 per month, might be sold as a generic for as little as $30 per month. This book examines the pay-for-delay program and how drug company pay-offs cost consumers billions.
Szczegóły produktu
Nova Science Publishers Inc
73110
9781611220711
9781611220711

Opis

Rok wydania
2011
Numer wydania
1
Oprawa
twarda
Wymiary (mm)
230.00 x 155.00
Waga (g)
316
  • Preface; Pay-for-Delay:: How Drug Company Pay-Offs Cost Consumers Billions; Pay-for-Delay Settlements in the Pharmaceutical Industry:: How Congress Can Stop Anticompetitive Conduct, Protect Consumers Wallets, & Help Pay for Health Care Reform (The $35 Billion Solution); Statement of The Federal Trade Commission, before the Subcommittee on Courts & Competition Policy, Hearing on Anticompetitive Pay-for-Delay Settlements in the Pharmaceutical Industry:: Why Consumers & the Federal Government are Paying Too Much for Prescription Drugs; Testimony of Heather Bresch, Chief Operating Officer, Mylan, Inc, before the Subcommittee on Courts & Competition Policy, Hearing on Pay to Delay:: Are Patent Settlements that Delay Generic Drug Market Entry Anticompetitive; Testimony of Bret M Dickey, Senior Vice President, Compass Lexecon, before the Subcommittee on Courts & Competition Policy, Hearing on Pay to Delay:: Are Patent Settlements that Delay Generic Drug Market Entry Anticompetitive; Statement of Guy Donatiello, Endo Pharmaceuticals Inc., before the Subcommittee on Courts & Competition Policy, Hearing on Pay to Delay:: Are Patent Settlements that Delay Generic Drug Market Entry Anticompetitive; Statement of William P. (Bill) Kennedy, Co-Owner, Nephron Pharmaceuticals Corporation, before the U.S. House of Representatives, Hearing on H.R. 1706, the Protecting Consumer Access to Generic Drugs Act of 2009; Testimony of William Vaughan, Senior Health Analyst, Consumers Union, Non-Profit Publisher of Consumer Reports, before the Subcommittee on Courts & Competition Policy, Hearing on Pay to Delay:: Are Patent Settlements that Delay Generic Drug Market Entry Anticompetitive; Index.
Komentarze (0)
Ostatnio przeglądane

  • Często kupowane razem

    Brak dostępnych produktów